1. Introduction {#sec1-viruses-08-00086}
===============

Mammalian retroviruses have been linked to a broad range of neoplastic and non-neoplastic pathologies, including hematological disorders, inflammatory diseases, immunodeficiencies, and neurodegenerative syndromes in various animals. With the striking exception of human T-cell leukemia and human immunodeficiency viruses (HTLV and HIV) for which the first strains were isolated in the early 1980s, the search and involvement of retroviruses in human diseases remain a subject of controversy \[[@B1-viruses-08-00086]\]. Claims that a *xenotropic* murine leukemia virus (XMRV)-related virus could infect humans, for example, have now been discredited, XMRV being a recombined mouse contaminant \[[@B2-viruses-08-00086],[@B3-viruses-08-00086],[@B4-viruses-08-00086],[@B5-viruses-08-00086]\]. Conversely, the presence of a mouse mammary tumor virus (MMTV)-related betaretrovirus in patients with liver autoimmune diseases or breast cancers remains a subject of debate \[[@B6-viruses-08-00086],[@B7-viruses-08-00086]\]. Recently, DNA related to the bovine leukemia virus (BLV) has also been found to be present in human breast tissue samples and to be significantly associated with breast cancer \[[@B8-viruses-08-00086],[@B9-viruses-08-00086]\].

Cross-species transmission of retroviruses among mammals is well established \[[@B10-viruses-08-00086],[@B11-viruses-08-00086]\], and it is thoroughly documented that both HTLV and HIV have emerged from their respective simian counterparts \[[@B12-viruses-08-00086],[@B13-viruses-08-00086],[@B14-viruses-08-00086]\]. Here, we evaluated whether sporadic infectious retrovirus transmissions have accompanied human autoimmune diseases that we selected for clinical manifestations that are reminiscent of retroviral infections. In this context, we focused on pediatric patients, reasoning that strong viremia is likely to accompany pediatric primary infections. Despite the wide array of retroviruses and idiopathic diseases monitored here, we did not find any indication of transmission of the panel of mammalian retroviruses we tested in any of the patient samples.

2. Materials and Methods {#sec2-viruses-08-00086}
========================

2.1. Pediatric Patients and Sample Collection {#sec2dot1-viruses-08-00086}
---------------------------------------------

We selected a panel of pediatric autoimmune diseases that fulfill either of three criteria: (i) diseases for which an infectious origin was suspected but never proved; (ii) symptoms that are reminiscent of human retroviral infections, such as HIV and HTLV-mediated cytopenia, autoimmune diseases, and vasculitis, all of which occur in HIV-infected patients \[[@B15-viruses-08-00086]\]; and (iii) other pathologies that mimic animal retroviral infections, thrombocytopenia, and autoimmune hemolytic anemia, frequently observed with gammaretrovirus infections \[[@B16-viruses-08-00086]\].

Blood samples, sera, and synovial fluid (in case of arthritis) or bone marrow cells (in case of hematologic diseases or cytopenia) were collected, in accordance with the French Ministry of Health ethical guidelines, from HIV-negative pediatric patients under 18 years of age admitted to the Montpellier University Hospital Center. No particular exposure of the patients to farm animals has been documented; nevertheless, direct contacts to domestic cats and indirect exposure to feral mice are likely. This study was approved by the ethics committee of the Délégation Régionale à la Recherche Clinique et à l\'Innovation Languedoc---Roussillon---Montpellier (N° DC-2009-1052). All patients, or their legal representatives, gave their written informed consent.

2.2. Mammalian Retrovirus Selection {#sec2dot2-viruses-08-00086}
-----------------------------------

We chose to monitor retroviruses that are able to infect human cell lines *in vitro.* We restricted our search to *env* sequences related to selected retroviruses and thus looked for potential infections with: simian T-cell leukemia virus (STLV)or human T-cell leukemia virus (HTLV) and BLV deltaretroviruses; MMTV, betaretroviruses that have been described in breast cancers and autoimmune cholangitis \[[@B1-viruses-08-00086],[@B7-viruses-08-00086]\]; the Mason-Pfizer monkey virus (MPMV), a betaretrovirus that causes cytopenia in macaques; and members of the gammaretrovirus genus, including the gibbon ape leukemia virus (GaLV), feline leukemia viruses (FeLV) and the infectious porcine endogenous retroviruses (PERV), which all use different receptors to enter human cells. BLV, FeLV, PERV, and MMTV were of special interest because of the close proximity and frequent contacts of their natural hosts with humans, and the xenotransplantation procedures using pig materials \[[@B10-viruses-08-00086],[@B17-viruses-08-00086]\].

2.3. Retrovirus Detection {#sec2dot3-viruses-08-00086}
-------------------------

We monitored two markers of retroviral presence, reverse transcriptase (RT) activity, and proviral DNA. RT in sera and synovial fluid cells was assessed according to the manufacturer's instructions with the highly sensitive non-radioactive ELISA C-type RT activity kit (Cavidi, Uppsala, Sweden) that efficiently targets gammaretroviruses, the prototype of which are murine leukemia viruses, including those that can infect human cells (xenotropic, polytropic, and amphotropic MLV). Sensitivity of all RT assays was assessed with the kit sample controls, with the expected range of sensitivity. DNA extraction was performed using the QIAamp blood kit (Qiagen, Courtaboeuf, France) as previously described \[[@B4-viruses-08-00086]\]. DNA concentrations were determined with a Nanodrop ND-1000 spectrophotometer. To verify the quality of DNA extracts, a region of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified using single-round PCR.

In addition, bacterial exploration with direct examination and culture was performed in all synovial fluid samples with no bacterial agent found. Briefly, all synovial fluid samples were inoculated onto standard agar for aerobic and anaerobic cultures during five days, and into Schaedler Broth up to 15 days, in accordance with the European guidelines \[[@B18-viruses-08-00086]\] ,and a smear was performed for Gram staining.

Using a multiple envelope alignment of available strains for each class of retrovirus, we were able to identify short highly conserved motifs, specific for each class, and scattered within the highly variable *env* region. We therefore designed specific primers that matched these highly conserved motifs, which are present in all members of a given class of *env* receptor-binding domain (RBD). These sets of primers distinguished BLV, FeLV, PERV, GaLV, MMTV, or MPMV while encompassing all members of each class ([Table 1](#viruses-08-00086-t001){ref-type="table"}). This strategy, with which we have identified new HTLV and STLV variants \[[@B19-viruses-08-00086]\], maintained the potential to isolate new retroviruses or variants that are likely to share those highly conserved short motifs.

PCR was performed based on a sensitive semi-nested assay initially developed to detect all known HTLV and STLV types (1--4) \[[@B19-viruses-08-00086]\]. Anchoring PCR on conserved motifs within the RBD, which is the most variable region of *env*, thus selectively enhanced detection of exogenous infections. To ensure the absence of detection of human endogenous retroviral DNA sequences, primer specificity was verified *in silico* \[[@B20-viruses-08-00086]\]. and confirmed experimentally using PCR performed on human peripheral blood mononuclear cell (PBMC) DNA from different individuals. Our PCR sensitivity was estimated either with *env*-containing plasmids diluted in PBMC DNA or, in the case of MPMV, with HEK-293T-infected cells harboring at least 1 viral copy per cell. The threshold sensitivity of all our PCR conditions corresponded to 10 to 20 copies per reaction in 500 ng of human PBMC DNA.

3. Results and Discussion {#sec3-viruses-08-00086}
=========================

We analyzed 120 samples for RT activity and 64 samples via PCR using High Fidelity Platinum® *Taq* DNA Polymerase (Life Technologies, Carlsbad, CA, USA) together, samples were obtained from a group of 110 children. As summarized in [Table 2](#viruses-08-00086-t002){ref-type="table"}, both *env* amplification and RT activity detection were free of retroviral signatures.

Despite the fact that we could not formally exclude traces of retroviral presence, our results strongly indicate that there was no link between these pathologies and infection with the wide range of retroviruses related to those we targeted.

The search for new retroviruses using PCR in samples from adult patients with a variety of diseases has led to many controversial results, in part due to contamination or background amplification of endogenous sequences \[[@B1-viruses-08-00086]\]. For some pediatric immune-mediated diseases, involvement of retroviruses has also been suspected, as in, for example, the search of RT activity in samples from children with Kawasaki disease, which led again to contradictory results \[[@B21-viruses-08-00086],[@B22-viruses-08-00086],[@B23-viruses-08-00086]\]. However, to our knowledge, our study is the first one that specifically investigated several retroviral infections as possible etiologic agents in a panel of pediatric autoimmune diseases.

Here, we used a new *env*-specific approach directed against retroviruses that we selected for their potential transmission to humans and in association with pediatric diseases. Efficient detection was achieved with nested PCR, or semi-nested PCR in the case of PTLV detection, while specificity was ensured by selecting an arrangement of consensus motifs within the Env RBD variable domains. We previously described the effectiveness of this method by detecting new HTLV-1/STLV-1 variants \[[@B19-viruses-08-00086]\] or HTLV-2/4 variants (unpublished results). While we are confident that the pediatric disease samples we tested did not contain retroviruses that harbor the targeted *env* sequences, we cannot formally eliminate the potential presence of infectious retroviruses that would harbor widely divergent *env*. Obviously, application of next-generation sequencing (NGS) techniques would greatly improve the monitoring for retroviral infections in human autoimmune diseases once reliable distinctions of potentially infectious exogenous retroviruses from human endogenous retroviral sequences can be made with deep sequencing \[[@B24-viruses-08-00086]\].
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viruses-08-00086-t001_Table 1

###### 

PCR primer sets used to amplify *env*-specific sequences from the indicated retroviruses.

  --------------------------------------------------------------------------------
  Virus   Primer Sequence 5' \-\-\--\> 3'               Genbank Accession Number
  ------- --------------------------------------------- --------------------------
  BLV     F1: CCAGACTTGGAGATGCTCCCTG (4707-4728) ^1^\   AF033818
          R1: GCACGGGCCTTCCCAGATTGTG (6443-6466)\       
          F2: GATGACAGCATATAACCAAGAGG (4749-4771)\      
          R2: GCCCAAATCTTCTGGGTCAACA (5347-5368)        

  FeLV    F1: ATTTTGCAGTTCACCCAGAAGG (6552-6573)\       NC_001940
          R1: TATACCGTACAGGATATGACCC (6619-6640)\       
          F2: GGTCTTAGGAACAGTCCCTATGC (6619-6640)\      
          R2: GGGGAGGGTTTGTTTGGTCGCTG (7069-7091)       

  PERV    F1: CTGAAAATCCCCTTAAGCTTCG (5542-5563)\       EU789636.1
          R1: ACATTGAATTTCCCTCCTCTAGCC (6504-6527)\     
          F2: TCCATCGCGTGGTTCCTTACTC (5566-5587)\       
          R2: GCTAAGCAAAGCCAACAAGAAG (6455-6476)        

  GaLV    F1: TGGCAGGTACTGTCCCAAACTGG (5720-5742)\      NC_001885.2
          R1: GTTAGGAAGGCCCCCTGCAC (6557-6577)\         
          F2: TGGGGAGCCGTAGGGTGCAGCTAC (5926-5950)\     
          R2: GGGAGGCGGAGTGTTTAGGGTAAC (6506-6529)      

  MMTV    F1: ACTTCACAAACTCCCCAAACCTC (6774-6796)\      AF228552.1
          R1: ACAGGGGGAGTATAATTTCCAAG (7462-7440)\      
          F2: GTGGGATGGGGAAGTACAGACC (6897-7918)\       
          R2: AGGAGAATTCTCCCAGAACCAAG(7519-7543)        

  MPMV    F1: CTTGTCACTGTGCTGGAGGATATG (5742-7765)\     NC_001550.1
          R1: GATCTCCTGACTGTAAGCACAGCC (6363-6387)\     
          F2: TCGATCTTTTCTTTACCACGGGC (6266-6282)\      
          R2: AAACTCCCTAAAATGGCAGTGTG (5832-5855)       
  --------------------------------------------------------------------------------

^1^: Numbers in parentheses indicate the position of each primer as in the corresponding GenBank sequence. BLV: bovine leukemia virus; FeLV: feline leukemia virus; PERV: porcine endogenous retrovirus; GaLV: gibbon ape leukemia virus; MMTV: mouse mammary tumor virus; MPMV: Mason-Pfizer monkey virus.

viruses-08-00086-t002_Table 2

###### 

Patient characteristics and processing of pediatric samples. PCR analyses were performed with the primer sets shown in [Table 1](#viruses-08-00086-t001){ref-type="table"}, designed specifically to amplify *env* sequences from BLV, FeLV, PERV, GaLV, MMTV, MMPV, and PTLV. MLV, FeLV, PERV or spumavirus presence was assayed by RT assay.

  ---------------------------------------------------------------------------------------------------------------------------------------
  Pathologies                         Patients (No.)   Age Range       Sample         PCR Analyses (Sample No.)   RT Assay (Sample No.)
  ----------------------------------- ---------------- --------------- -------------- --------------------------- -----------------------
  Acute thrombocytopenia ^1^          35               2 mos--17 yrs   Whole blood\   10\                         NA\
                                                                       Serum          NA                          31

                                                                       Bone marrow    3                           NA

  Autoimmune hemolytic anemia         3                4--16 yrs       Whole blood\   3\                          NA\
                                                                       Serum          NA                          3

                                                                       Bone marrow    1                           NA

  Juvenile idiopathic arthritis ^2^   59               1--15 yrs       Whole blood    15                          NA

  Serum                               NA               24                                                         

  Bone marrow                         1                NA                                                         

  Synovial fluid                      28               49                                                         

  Henoch-Schönlein disease            9                2--13 yrs       Whole blood    3                           NA

  Serum                               NA               9                                                          

  Kawasaki disease                    4                7 mos--3 yrs    Serum          NA                          4

  Total                               110                                             64                          120
  ---------------------------------------------------------------------------------------------------------------------------------------

^1^: Including 29 idiopathic thrombocytopenic purpura, 6 documented infectious-associated thrombocytopenia (1 enterovirus, 2 cytomegalovirus, 2 Epstein Barr Virus, 1 parvovirus); ^2^: Including 41 oligoarticular, 14 polyarticular, 3 HLAB27-positive, 2 systemic onset; RT: Reverse transcriptase; mos: months; yrs: years.
